H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio Holdings, Inc., and ADx NeuroSciences NV today announced the acquisition of ADx NeuroSciences by Fujirebio for 40 million euros. Pending
In partnership with ADx NeuroSciences, Fujirebio has recently launched two new tests for the novel biomarkers NPTX2 and sTREM2 that can aid in exploring new pathways in the understanding of this disease and support the development of pharmacological therapies.